Loading stock data…
RCKT
$2.65-0.05 (-1.67%)
Market OpenUpdated 3:53 PM EDT
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rocket Pharmaceuticals, Inc. in the Healthcare sector is trading at $2.65. Wall Street consensus targets $9.39 (11 analysts), implying a +253.5% move over the next 12 months. The stock is currently near its 52-week low of $2.40, remaining 25.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +253.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.65
Potential Downside
0%
Whystock Fair Value$2.65
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$9.39+253.5%
Range$3.00 – $16.00
Fundamentals
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-87.96%
Volume
Today's trading volume
2.34M
Recent News
Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going?
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) is one of the best gene therapy stocks to buy in 2026. The Street expects Rocket Pharmaceuticals’ stock to explode 180% over the next 12 months. On April 28, Leerink Partners boosted its price target on Rocket Pharmaceuticals shares to $12 from $11 while keeping a Market Perform rating on the […]
Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the best NASDAQ stocks under $5 to buy right now. On May 7, Rocket Pharmaceuticals reported a Q1 2026 net loss of $47.6 million ($0.42 per share). Driven by a recent realignment and lower headcount, R&D expenses fell to $31.5 million, and G&A expenses dropped to $17.1 million. […]
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.
Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says
Rocket Pharmaceuticals' (RCKT) clinical and regulatory updates on its three cardiac gene therapy pro
3 Promising Penny Stocks With Market Caps Up To $600M
The market has climbed 1.8% in the last 7 days and is up 30% over the past year, with earnings projected to grow by 16% annually. Penny stocks, while a somewhat outdated term, continue to represent intriguing investment opportunities for those looking beyond major corporations. With strong financial health and solid fundamentals, these smaller or newer companies can offer potential growth at lower price points.